Effect of preoperative administration of proprotein convertase subtilisin/kexin type 9 inhibitor on carotid artery stenting.
Perioperative embolic stroke is one of the most serious complications during carotid artery stenting (CAS). Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is a low-density lipoprotein (LDL)-lowering drug that inhibits PCSK9, which normally binds to the LDL-C receptor. Its combination with statin significantly decreases LDL-cholesterol levels. PCSK9i is expected to achieve lower LDL-C levels than single use of statin. This study aimed to investigate whether perioperative PCSK9i administration stabilizes carotid artery plaque and reduces perioperative complications of CAS. Nine patients with symptomatic stenosis [North American Symptomatic Carotid Endarterectomy (NASCET) 50%] or asymptomatic stenosis (NASCET 80%) were included. PCSK9i was administered at least twice (once in 2 weeks) in the outpatient clinic before CAS. Perioperative complications; results from blood tests, magnetic resonance imaging (MRI), MR angiography, and carotid ultrasonography (US); and modified Rankin scale score at discharge were assessed. High intensity on diffusion-weighted imaging was not observed in eight patients. Changes in carotid plaque characteristics were found with MRI and/or carotid US in seven patients. The plaque/muscle ratio decreased in three patients. The carotid plaque became hyperechoic in two patients, and the fibrous cap was seen more clearly on carotid US. Two patients had findings of stabilized plaque on MRI and carotid US, which indicates that plaque transformation was more stable. Lowering LDL-C level could reduce ischemic complication, and low LDL-C level affects plaque stability and anti-thrombus formation. PCSK9i can possibly stabilize carotid plaque and reduce perioperative complications of CAS.